The invention is directed to triazolopyridazine compounds of Formula I: where R.sup.1, R.sup.5, R.sup.6, R.sup.7, R.sup.8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

 
Web www.patentalert.com

> Cytotoxicity mediation of cells evidencing surface expression of TROP-2

~ 00373